UCB Japan Obtains FDA Approval of Treatment Drug for Epilepsy Patients.Tokyo, Japan, Aug 14, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - UCB UCB - University of California at Berkeley Japan, a leading global biopharmaceutical company has obtained the approval of Keppra - generic name generic name n. 1. The official nonproprietary name of a drug, under which it is licensed and identified by the manufacturer. 2. levetiracetam - 500mg/5mL (100mg/mL) from the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for use as an adjunctive therapy for treatment of partial-onset seizures in adults with epilepsy. The 15- minute intravenous infusion of Keppra offers an alternative for patients who find oral administration difficult or temporarily not feasible. The drug is prescribed to adults and children four years of age and older with epilepsy. Keppra has already been approved in March 2006 from the European Commission. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion